TYBR Health discloses $14.35 million raised in ongoing equity offering
The Houston-based biotechnology company filed a Form D showing sales toward a $30 million target, with $15.65 million still to be sold.
TYBR Health, Inc. filed a Form D notice with the Securities and Exchange Commission disclosing details of an ongoing securities offering. The filing lists a date of first sale of 2026-07-091 and was signed on 2026-07-22 by Timothy J Keane Jr, CEO1.
The company is based at 2450 Holcombe Blvd., Suite X, Houston, Texas 770211 and is incorporated in Delaware, organized over five years ago1. TYBR Health classifies its industry as biotechnology under the health care category1.
According to the filing, the total offering amount is $30,000,000, with $14,354,342 already sold and $15,645,658 remaining to be sold1. The offering is being conducted under Rule 506(b)1 and is expected to last no more than one year1. The company reported a minimum investment of $0 from any outside investor1 and stated that 12 investors have already invested in the offering1.
The filing indicates no sales commissions or finders' fees have been paid1, and no proceeds have gone to executive officers, directors, or promoters1. The notice also states the offering is not being made in connection with a business combination transaction such as a merger or acquisition1.
Related persons listed in the filing include Timothy J. Keane Jr. and Alex Smith, both identified as executive officers and directors1, along with directors Aaron Smith, Jeffrey Tyber, Greg Banker, Liz Zambory, and Toby Hamilton.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.